Innovation Pharmaceuticals Inc (IPIX)

[Phoenix300]

MD Anderson..Kevetrin..Amgen 900 trials at MD Anderson

Progressive finds AMGEN 900 listing Kevetrin in patent

June 26, 2013
Beverly, MA — 06/26/13 — Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces today that the Company has signed a Material Transfer Agreement (MTA) with The University of Texas M.D. Anderson Cancer Center (“MD Anderson”). Per the MTA, Cellceutix will provide MD Anderson with Kevetrin, the Company’s novel anti-cancer drug candidate, for laboratory research of Kevetrin as a potential new treatment for Lymphoma and Multiple Myeloma.

http://www.amgentrials.com/amgen/trialsummary.aspx?studyid=20101351#locn

One of the Amgen trial locations has MD Anderson's zip code listed

Cellceutix admits to supplying MD Anderson with Kevetrin